Fredun Pharmaceuticals Limited FREDUN NSEPHARMA
Company Overview
Fredun Pharmaceuticals Limited manufactures and sells pharmaceutical formulations, dietary/herbal supplements, nutraceuticals, animal healthcare products, cosmeceuticals, mobility and rehabilitation products, and other healthcare products in India, Africa, Southeast Asia, Commonwealth of Independent States countries, MENA region, and Latin America. The company offers allopathic formulations, including analgesics/NSAID, antacid/antiulcer, anthelmintic, antibacterial, anti-diabetic, anti-inflammatory, anti-malarial, anti-obesity, antacid, anthelmintic, anticoagulants, anticonvulsants, antidiarrhoeal, antidepressant, antifungal, antihistamines/antiallergic, antihypertensives, antiviral, bone modulating drugs, bronchodilators and anti-asthma drugs, calcium tablets, cardiovascular, diuretic, impotence drugs, laxative, and appetite stimulant with multivitamins. It also provides surgical products, such as IV fluids and cannulas, disposable syringes, infusion sets, surgical gloves and cottons, and personal healthcare products; APIs; direct compressible granules; pellets; animal healthcare products; aqua products; and niche products. Additionally, the company offers therapeutic products under the brand Hormone Range Products, a specialty therapeutics brand focused on longevity, hormone health, recovery science, and human performance solutions. Fredun Pharmaceuticals Limited was incorporated in 1987 and is headquartered in Mumbai, India.,
Why Investors Should Care
Return on capital employed stands at 27.3%.
Net profit has compounded at 44.5% per year over the last five years.
Revenue has grown at a 32.2% CAGR over the past five years.
Recent Developments
- Mar 2026 Revenue of ₹633.33 Cr (+40.2% YoY); net profit ₹32.62 Cr.
- Trailing 12 Months Year-on-year growth — revenue +90.7%, earnings +281.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 32.2%, profit CAGR 44.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 32.16% |
| 1 Year: | 90.70% |
Compounded Profit Growth
| 5 Years: | 44.52% |
| 1 Year: | 281.40% |
Stock Price Performance
| 1 Year: | -3.18% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | +3.17% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- RSI (14)45.52 · Neutral
P/E of 60.32 is above the sector median of 35.90 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 27.3%.
- Compounding revenue at 32.2% over 5 years.
- Profit CAGR of 44.5% over 5 years.
CONS
- Trading at a high P/E of 60.3.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | FREDUN Fredun Pharmaceuticals Limited NSEPHARMA | 1,391.00 | 60.32 | ₹2,350.74 Cr | 0.05% | 27.29% | 11.58% | 32.16% | 44.52% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,758.00 | 34.88 | ₹4.22 L Cr | 0.91% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,162.00 | 83.32 | ₹2.43 L Cr | 0.32% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,615.30 | 73.73 | ₹1.76 L Cr | 0.81% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,135.00 | 25.30 | ₹1.13 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 6 | LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA | 634.25 | 165.17 | ₹1.10 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 7,604.50 | 52.35 | ₹1.09 L Cr | 0.25% | 19.20% | 20.48% | 14.85% | 33.34% |
| 8 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 2,002.50 | 98.99 | ₹1.08 L Cr | 0.12% | 19.53% | 16.77% | 3.77% | 4.00% |
| 9 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,330.90 | 31.92 | ₹1.08 L Cr | 0.99% | 14.86% | 11.27% | 7.23% | 11.45% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 119.40 Cr | 143.59 Cr | 159.93 Cr | 210.41 Cr | 227.76 Cr |
| Cost of Revenue | 87.30 Cr | 107.33 Cr | 114.00 Cr | 156.10 Cr | 176.19 Cr |
| Gross Profit | 32.10 Cr | 36.25 Cr | 45.92 Cr | 54.31 Cr | 51.57 Cr |
| Operating Expenses | 16.53 Cr | 15.82 Cr | 21.37 Cr | 28.58 Cr | 22.40 Cr |
| Operating Income | 15.57 Cr | 20.44 Cr | 24.55 Cr | 25.73 Cr | 29.17 Cr |
| EBITDA | 16.99 Cr | 22.33 Cr | 26.34 Cr | 28.88 Cr | 32.74 Cr |
| Interest Expense | 6.53 Cr | 7.73 Cr | 10.55 Cr | 14.49 Cr | 8.62 Cr |
| Pretax Income | 9.04 Cr | 12.71 Cr | 14.00 Cr | 11.25 Cr | 20.55 Cr |
| Tax Provision | 2.27 Cr | 3.27 Cr | 3.52 Cr | 46.81 L | 7.42 Cr |
| Net Income | 6.77 Cr | 9.43 Cr | 10.48 Cr | 10.78 Cr | 13.13 Cr |
| Diluted EPS | - | - | - | - | - |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 274.34 Cr | 346.58 Cr | 451.71 Cr | 633.33 Cr |
| Cost of Revenue | - | 217.43 Cr | 273.60 Cr | 345.49 Cr | 464.74 Cr |
| Gross Profit | - | 56.91 Cr | 72.98 Cr | 106.21 Cr | 168.59 Cr |
| Operating Expenses | - | 31.91 Cr | 38.78 Cr | 49.58 Cr | 74.37 Cr |
| Operating Income | - | 24.99 Cr | 34.20 Cr | 56.63 Cr | 94.22 Cr |
| EBITDA | - | 27.88 Cr | 37.77 Cr | 52.96 Cr | 92.73 Cr |
| Interest Expense | - | 7.56 Cr | 12.52 Cr | 20.42 Cr | 37.49 Cr |
| Pretax Income | - | 17.51 Cr | 21.45 Cr | 27.49 Cr | 47.00 Cr |
| Tax Provision | - | 6.70 Cr | 5.83 Cr | 7.75 Cr | 14.38 Cr |
| Net Income | - | 10.81 Cr | 15.62 Cr | 19.74 Cr | 32.62 Cr |
| Diluted EPS | - | 7.64 | 11.11 | 0.00 | 0.00 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 257.28 Cr | 307.60 Cr | 487.41 Cr | 642.08 Cr |
| Current Assets | - | 216.21 Cr | 257.20 Cr | 427.20 Cr | 498.17 Cr |
| Cash & Equivalents | - | 2.95 Cr | 1.07 Cr | 63.69 L | 64.93 Cr |
| Inventory | - | 150.12 Cr | 175.00 Cr | 239.89 Cr | 269.80 Cr |
| Receivables | - | 34.56 Cr | 64.85 Cr | 177.12 Cr | 92.69 Cr |
| Total Liabilities | - | 160.90 Cr | 186.13 Cr | 346.03 Cr | 360.46 Cr |
| Current Liabilities | - | 139.66 Cr | 166.83 Cr | 328.10 Cr | 296.86 Cr |
| Long Term Debt | - | 15.44 Cr | 12.80 Cr | 9.61 Cr | 56.31 Cr |
| Total Debt | - | 86.55 Cr | 105.51 Cr | 168.38 Cr | 242.27 Cr |
| Total Equity | - | 96.38 Cr | 121.47 Cr | 141.38 Cr | 281.62 Cr |
| Shares Outstanding | - | 1.36 Cr | 1.41 Cr | 1.42 Cr | 1.64 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -14.41 Cr | -43.87 L | -16.60 Cr | 11.90 Cr |
| Investing Cash Flow | - | -9.40 Cr | -7.64 Cr | -6.35 Cr | -73.59 Cr |
| Financing Cash Flow | - | 25.18 Cr | 5.99 Cr | 26.65 Cr | 121.45 Cr |
| Capital Expenditure | - | -9.49 Cr | -7.64 Cr | -6.11 Cr | -73.59 Cr |
| Free Cash Flow | - | -23.90 Cr | -8.08 Cr | -22.70 Cr | -61.69 Cr |
| Net Change in Cash | - | 1.36 Cr | -2.08 Cr | 3.70 Cr | 59.76 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 20.7% | 21.1% | 23.5% | 26.6% |
| Operating Margin % | - | 9.1% | 9.9% | 12.5% | 14.9% |
| Net Margin % | - | 3.9% | 4.5% | 4.4% | 5.2% |
| ROE % | - | 11.2% | 12.9% | 14.0% | 11.6% |
| ROCE % | - | 21.2% | 24.3% | 35.5% | 27.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for FREDUN
Fredun Pharmaceuticals | Stock Share Price Live - MarketSmith India
<a href="https://news.google.com/rss/articles/CBMib0FVX3lxTE13UzlYLW1IaFEyQ3p5SHlkX1B6Y1BzNWl2Z2NVbmUtNkV2TWYzRWdoRWsyY2FpdmhDQzJtUU5LaEJiOFhBaFR2WjhLUTc2Q2lfX1Y1ZERvYkJWXzBNblpRS2pUQ2hWRzZ4N3JHTjRPSQ?oc=5" target="_blank">Fredun Pharmaceut…
Bonus issue alert! Last day to buy this microcap pharma stock that rallied 200% in one year - The Economic Times
<a href="https://news.google.com/rss/articles/CBMi9gFBVV95cUxNZmJPbENMV1oydlFjSFJ0Q01GMlUtTG5OcTl6WUZuUF93S1VlUkgzZy0zNUhaWEU4WmNwdl9JeENWenNxVUlSZkhrYVVlSHNlU0czNmZjN1hyX0Z6SXJBQzhLTHFKWHlYN0FRV1R3X0lJdkN1UXNMbTNOeDFGNmhnRVBvMDNROF9xR1ZzNk…
Fredun Pharmaceuticals Ltd. Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxQU0JaalFKUVVsYy1CV0dfUTByc2V0NmVhNGNsZFNhZ2k0UW9NVE1hT0JmQ1U2Tm5nWDlIOENjUEJmVHY2UzJoQ0FYaXgteTd0ZTNfdklZS2tUa1N3RE44UE1HdGxqclViUjhLdWhSQ1NYNE9JdDg4SjJFSng4QVB0MjVHMWlGWlVKei1PT1…
Fredun Pharma acquires pet-wellness brand Furlicks - Business Standard
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxPb2c5T24zVW5BVzB1QkhpU093a2F4RFVTZS0yU3B6U3pRNU56Z1A1YzhtVEpxclNEMUt3ZHlxaFB1OFd5WEdFMU1lWmJTRE12bEhfZThKYURNdjlyZnl1OGl1dmRhY0xOcDN5WGFVbVdjc1lxdWV0UXhnX0gtUGhzZWczVFlHcjFJbElaLU…
Fredun Pharmaceuticals Delivers Stellar Q1 FY27 Performance; Revenue Jumps 90%, EBITDA Surges 93% and Profit Rises 95% YoY - ANI News
<a href="https://news.google.com/rss/articles/CBMi_AFBVV95cUxONk5XbzQ3OHVMb3VTM21pajMwai02UXUzaEhsQ3RHd2N1UnFVN0h3UmxWT2xIVHd5eHdXNXo5RmVUcjhHWmdOLXBwY250dnNteG5HWjNPbDVwRTdUclFzWFUxLWhYOWNmRjJOOHRHRVpWZE1hQ0NTTWJ0czVEOEljZHF3TEZZWklxTXROZH…
FREDUN PHARMA Share Price Today Up 5% - Equitymaster
<a href="https://news.google.com/rss/articles/CBMiowJBVV95cUxQMGtzRFRXcDgyT2NUQWwwVjJ5Z0pKZXUtbUMyVWNBc2xXWTBZdjNfaWRuaFJBNGNpWVkxRzVTSG1zWjQ3NXcxOGQzMlZ2WDZuVWRLOXAxTXBqdkFFbm5sRlFqM3MzMEtYZk1TRUQ4Vkh5RW5uYjEwVktHQXdMaDh1WmQwOWtFRl9FLWFmSF…
FREDUN — Frequently Asked Questions
What is the current share price of Fredun Pharmaceuticals Limited (FREDUN)?
As of 2026-10-24 04:55 IST, Fredun Pharmaceuticals Limited (FREDUN) trades at ₹1,391.00 on NSE. Its 52-week range is ₹1,221.60 to ₹1,552.30.
What is the market capitalisation of FREDUN?
Fredun Pharmaceuticals Limited (FREDUN) has a market capitalisation of ₹2,350.74 Cr on NSE.
What is the P/E ratio of FREDUN?
FREDUN trades at a trailing price-to-earnings (P/E) ratio of 60.32. The industry average P/E is 35.90. Its price-to-book (P/B) ratio is 8.01.
Does FREDUN pay a dividend?
Fredun Pharmaceuticals Limited (FREDUN) currently offers a dividend yield of 0.05%.
What is the return on equity (ROE) of FREDUN?
FREDUN has a return on equity (ROE) of 11.58%. Its return on capital employed (ROCE) is 27.29%.
Is FREDUN a good stock to buy?
This page provides a data-driven analysis of Fredun Pharmaceuticals Limited (FREDUN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.